OrphanDrug
OrphanDrug
Pharma Knowledge Base

Acoramidis

Orphan DrugFDA Approved (2024)

Contents

  1. 1. Description
  2. 2. Indications
  3. 3. Global Availability
  4. 4. Suppliers & Distributors

Description

A near-complete oral transthyretin (TTR) stabilizer for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). FDA-approved November 2024 to reduce cardiovascular death and hospitalization.

Indications & Therapeutic Use

Transthyretin amyloid cardiomyopathy (ATTR-CM)

Linked Diseases:

Hereditary transthyretin amyloidosis
5C84.0D000071170

Evidence: FDA-approved indication

Global Availability (1 countries)

CountryAccess RouteRegulatory PathwayLead TimeStatus
USUnited States of America
Standard Marketing Authorization——Approved

Available Through

This drug is available for procurement through the following fulfilment partner.

Fulfilment Partner
Acoramidis
Generic Nameacoramidis
Brands1 brand available
Active Ingredientacoramidis
Drug ClassTransthyretin amyloid cardiomyopathy (ATTR-CM)
ManufacturerBridgeBio Pharma
Orphan StatusYes — Orphan Drug
Cold ChainNot Required
Reg. StatusFDA Approved (2024)
Countries1 countries
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes